RecruitingPhase 2NCT07562087
A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure
Studying Lyme disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Tarsus Pharmaceuticals, Inc.
- Intervention
- TP-05 (lotilaner) Low Dose(drug)
- Enrollment
- 700 target
- Eligibility
- 18-70 years · All sexes
- Timeline
- 2026 – 2027
Study locations (19)
- Study Site, Pikesville, Maryland, United States
- Study Site, Brookline, Massachusetts, United States
- Study Site, Fall River, Massachusetts, United States
- Study Site, Minneapolis, Minnesota, United States
- Study Site, Marlboro, New Jersey, United States
- Study Site, Albany, New York, United States
- Study Site, Binghamton, New York, United States
- Study Site, Buffalo, New York, United States
- Study Site, East Syracuse, New York, United States
- Study Site, Middletown, New York, United States
- Study Site, New York, New York, United States
- Study Site, Rochester, New York, United States
- Study Site, Erie, Pennsylvania, United States
- Study Site, Hatboro, Pennsylvania, United States
- Study Site, Philadelphia, Pennsylvania, United States
- +4 more locations on ClinicalTrials.gov
Collaborators
PPD Development, LP
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07562087 on ClinicalTrials.govOther trials for Lyme disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07561294A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982 to Prevent Lyme Disease in Healthy Participants (18 to 70 Years of Age)ModernaTX, Inc.
- RECRUITINGPHASE3NCT07500506A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease VaccinePfizer
- RECRUITINGPHASE1, PHASE2NCT06785402Ceftriaxone for Post-Treatment Lyme DiseaseHackensack Meridian Health
- ACTIVE NOT RECRUITINGPHASE3NCT07226882A Study to Learn About Different Dosing Schedules of a Lyme Disease Vaccine in Healthy AdultsPfizer
- RECRUITINGPHASE4NCT06451913Effect of Saccharomyces Boulardii CNCM I-745 on Gut Microbiota in Patients Undergoing Antibiotic Therapy (in the Context of Erythema Migrans (Early Skin Form of Lyme Borreliosis))Biocodex
- RECRUITINGNANCT06915324Transcranial Direct Current Stimulation for Post Treatment Lyme DiseaseColumbia University
- RECRUITINGEARLY PHASE1NCT06611111Ceftriaxone Pulse Dose for Post-Treatment Lyme DiseaseState University of New York - Upstate Medical University
- ACTIVE NOT RECRUITINGNCT06835075Clinicaly Manifested Reinfections with Borrelia Burgdorferi Sensu LatoUniversity Medical Centre Ljubljana